A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome

Area of Science:

• Biochemistry
• Oncology
• Metabolomics

Background:

• Chemotherapy efficacy monitoring is crucial for personalized cancer treatment.
• Identifying reliable biomarkers for treatment response remains a challenge.

Purpose of the Study:

• To develop and validate a biomarker-based approach using metabolomics to monitor chemotherapy efficacy.
• To identify metabolomic signatures indicative of treatment response and resistance in hepatocellular carcinoma.

Main Methods:

• In vitro studies using tumor cell lines exposed to chemotherapeutics, analyzing extracellular metabolome changes.
• Gas chromatography-mass spectrometry analysis of serum samples from a Phase II clinical trial of axitinib in advanced hepatocellular carcinoma patients.
• Correlation of metabolomic data with CT scan-assessed treatment response and tumor growth.

Main Results:

• In vitro, distinct metabolomic patterns correlated with growth inhibition and cell death.
• In vivo, a robust clinical metabolomic signature emerged within 4 weeks, distinguishing responders from non-responders.
• These predictive metabolomic changes diminished upon tumor regrowth, indicating resistance.

Conclusions:

• Serial metabolomic monitoring can effectively track chemotherapy efficacy and detect emerging resistance.
• This approach provides a dynamic tool for oncologists to guide treatment modifications in real-time.
• Biomarker-based metabolomic analysis offers a promising strategy for optimizing cancer therapy.